You Position: Home > Paper
Strategy of molecular drug design: hits, leads and drug candidates
( views:283, downloads:17 )
- Author:
- No author available
- Journal Title:
- ACTA PHARMACEUTICA SINICA
- Issue:
- 9
- DOI:
- 10.3321/j.issn:0513-4870.2008.09.004
- Key Word:
- 分子设计;苗头化合物;先导物;候选药物;配体效率;优化
Abstract： 苗头化合物-先导物-候选药物是创制新药的三个重要里程碑,其中候选药物的确定是新药创制的关键环节,将创制过程分成研究和开发两个阶段,并且开发阶段所有环节都取决于候选药物的化学结构,所以决定了临床前和临床研究的命运.候选药物质量的高低又受制于先导化合物的类药性和苗头化合物的品质,苗头化合物演化成先导物是将新药的研究植根于有研发前景的结构上,先导物的优化是将活性化合物转化成候选药物的过程,是在药效、药代、安全性和物化性质等多维空间中的优化操作.本文结合实例讨论了发现苗头、确定先导物、先导物优化和确定候选药物的策略原则.
- [1]M M, Hann,A R, Leach,G, Harper.Molecular complexity and its impact on the probability of finding leads for drug discovery.[J].1900,41(3).
- [2]Hiroyuki Kagechika,Emiko Kawachi,Yuichi Hashimoto,etc.Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity[J].1988,31(11).
- [3]Boden K,Brough S,Bennion C,etc.Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists.[J].2003,13(16).
- [4]Allan P. Marchington,Donald S. Middleton,Barry C. Jones,etc.Structure-Activity Relationships of 1-Alkyl-5-(3,4-dichlorophenyl)-5-{2-[(3-substituted)-1-azetidinyl]ethyl}-2-piperidones. 1. Selective Antagonists of the Neurokinin-2 Receptor[J].2002,45(24).
- [5]J L, Flanagan,C C, Willhite,V H, Ferm.Comparative teratogenic activity of cancer chemopreventive retinoidal benzoic acid congeners (arotinoids).[J].1987,78.
- [6]Hajduk PJ,Greer J.A decade of fragment-based drug design: strategic advances and lessons learned.[J].2007,6(3).
- [7]Marcus F. Boehm,Lin Zhang,Beth Ann Badea,etc.Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids[J].1994,37(18).
- [8]Cele AZ,Metz JT.Ligand efficiency indices as guideposts for drug discovery.[J].2005,10(7).
- [9]P. R. Andrews,D. J. Craik,J. L. Martin.Functional group contributions to drug-receptor interactions[J].1984,27(12).
- [10]Chauret N,Guay D,Li C,etc.Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding.[J].2002,12(16).
- [11]Simon J. Teague,Andrew M. Davis,Paul D. Leeson and,etc.The Design of Leadlike Combinatorial Libraries[J].1999,38(24).
- [12]Syndeep Dugar,Nathan Yumibe,John W. Clader,etc.Metabolism and structure activity data based drug design: discovery of (-) SCH 53079 an analog of the potent cholesterol absorption inhibitor (-) SCH 48461[J].1996,6(11).
- [13]Kuntz ID,Chen K,Sharp KA,etc.The maximal affinity of ligands.[J].1999,96(18).
- [14]Proudfoot JR.Drugs, leads, and drug-likeness: an analysis of some recently launched drugs.[J].2002,12(12).
- [15]Siegal G,Ab E,Schultz J.Integration of fragment screening and library design.[J].2007,12(23).
- [16]Burnett DA,Clader JW,Rosenblum SB,etc.Discovery of 1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.[J].1998,41(6).
- [17]Saxty G,Garrett MD,Verdonk ML,etc.Identification of inhibitors of protein kinase B using fragment-based lead discovery[J].2007,50(10).
- [18]Roger Lahana.How many leads from HTS?[J].1999,4(10).